TABLE 3.

The magnitude of the increase in the immunoreactive score (IRS) between the HGD or T1 colorectal cancer (T1CRC) component and the normal or LGD component if an increase was present, expressed as mean and 95% confidence interval.

Target	Increase in IRS between the HGD‐T1CRC and normal component	Increase in IRS between the HGD‐T1CRC and LGD component
	Mean (95%CI)	Mean (95%CI)
CEA	6.0 (5.0–7.0), n = 46	4.5 (3.4–5.5), n = 38
c‐MET	4.4 (3.8–5.1), n = 46	3.0 (2.2–3.9), n = 25
EpCAM	4.3 (4.0–4.6), n = 40	5.0 (3.5–6.5), n = 10
FRα	3.6 (2.6–4.5), n = 20	2.9 (1.8–4.0), n = 13
αvβ6	2.9 (2.0–3.7), n = 14	2.3 (1.0–3.7), n = 9

Abbreviations: CEA, carcinoembryonic antigen; CI, confidence interval; c‐MET, c‐mesenchymal‐epithelial transition factor; CRC, colorectal cancer; EpCAM, epithelial cell adhesion molecule; FRα, folate receptor alpha; HGD, high‐grade dysplasia; IRS, immunoreactive score; LGD, low‐grade dysplasia.